AVEO Pharmaceuticals

OverviewSuggest Edit

AVEO Pharmaceuticals is a biopharmaceutical company that provides a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company develops Tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) for the treatment of adult patients with advanced renal cell carcinoma. It offers therapies for cancer using proprietary genetic model systems that enable the identification of essential targets critical to the origin, maintenance and spread of malignant tumors.
TypePublic
Founded2001
HQBoston, MA, US
Websiteaveooncology.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Dec 2019)19(+12%)
Revenue (FY, 2020)$6 M(-79%)
Share Price (Jun 2022)$6.6(+10%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at AVEO Pharmaceuticals

Erick Lucera

Erick Lucera

Chief Financial Officer
Kenneth M. Bate

Kenneth M. Bate

Chairman of the Board of Directors
Michael P. Bailey

Michael P. Bailey

President, Chief Executive Officer and Director
Emile Farhan

Emile Farhan

Senior Vice President of Technical Operations and Quality Assurance
Lisa Bruneau

Lisa Bruneau

Vice President, Finance
Anthony B. Evnin

Anthony B. Evnin

Director
Show more

AVEO Pharmaceuticals Office Locations

AVEO Pharmaceuticals has an office in Boston
Boston, MA, US (HQ)
30 Winter Pl
Show all (1)

AVEO Pharmaceuticals Financials and Metrics

AVEO Pharmaceuticals Revenue

AVEO Pharmaceuticals's revenue was reported to be $6.02 m in FY, 2020
USD

Revenue (Q1, 2021)

1.9m

Net income (Q1, 2021)

(22.1m)

EBIT (Q1, 2021)

(19.1m)

Market capitalization (24-Jun-2022)

226.2m

Closing stock price (24-Jun-2022)

6.6

Cash (31-Mar-2021)

121.4m

EV

161.7m
AVEO Pharmaceuticals's current market capitalization is $226.2 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

164.8m19.3m1.3m18.1m19.0m2.5m7.6m5.4m28.8m6.0m

Revenue growth, %

1302%

General and administrative expense

29.2m36.9m28.7m18.6m14.2m8.2m9.1m10.8m11.2m22.2m

R&D expense

101.7m91.4m68.5m38.3m12.9m23.7m25.2m20.7m18.0m22.7m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

43.5m76.1m50.8m52.3m26.6m15.1m14.9m24.4m29.8m61.8m

Accounts Receivable

7.2m20.6m984.0k2.3m4.6m1.0m402.0k3.0m1.6m1.2m

Prepaid Expenses

6.1m9.4m3.0m1.5m1.6m

Current Assets

234.4m190.7m128.9m59.1m40.4m26.3m50.2m27.9m50.6m65.5m
USDQ2, 2011

Financial Leverage

1.3 x
Show all financial metrics

AVEO Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

AVEO Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

AVEO Pharmaceuticals Online and Social Media Presence

Embed Graph

AVEO Pharmaceuticals News and Updates

Thinking about buying stock in Edesa Biotech, AVEO Pharmaceuticals, Lucid Group, FuelCell Energy, or Nikola Corp?

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EDSA, AVEO, LCID, FCEL, and NKLA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Thinking about buying stock in Myomo Inc, Parsley Energy, Fortress Biotech, AVEO Pharmaceuticals, or Nio Inc?

NEW YORK, Sept. 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MYO, PE, FBIO, AVEO, and NIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in AVEO Pharmaceuticals, CAN-FITE Biopharma, Francesca's, AT&T, or Tilray?

NEW YORK, Sept. 10, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVEO, CANF, FRAN, T, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -AVEO

NEW YORK, April 9, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc. ("Aveo" or the "Company") (NASDAQ: AVEO) and certain of its officers and directors. The class action, filed in United States District Court,...

Thinking about buying stock in Aurora Cannabis Inc., Advanced Micro Devices, Aveo Pharmaceuticals, Dave & Buster's, or Riot Blockchain Inc.?

NEW YORK, April 3, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AMD, AVEO, PLAY, and RIOT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Aveo Pharmaceuticals, Lululemon Athletica Inc., Navios Maritime, Quantenna Communications Inc., or Reebonz Ltd.?

NEW YORK, March 28, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVEO, LULU, NMCI, QTNA, and RBZ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

AVEO Pharmaceuticals Blogs

AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting

Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with PFS at 1 year demonstrated a 55% reduction in risk of death on tivozanib as compared to sorafenib Latest analysis of Phase 2 study show tivozanib demonstrated promising activity in nccRCC patients, a

AVEO Oncology Reports First Quarter 2022 Financial Results

AVEO Oncology Reports First Quarter 2022 Financial Results Content Import Thu, 05/05/2022 - 07:00 AVEO Oncology Reports First Quarter 2022 Financial Results May 05 | 2022 Earnings – Total Q1 2022 Net Revenue of $20.9 Million including $20.1 Million …

AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022 Content Import Thu, 04/28/2022 - 08:30 AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022 Apr 28…

Manager/Senior Manager, Clinical Supply Manager

Location: Remote Description: The Manager/Senior Manager, Clinical Supply Manager, is responsible for coordination of investigational medicinal product (IMP) supply planning, forecasting, labeling, packaging, distribution, inventory monitoring, and reconciliation for assigned clinical studies. Respo…

NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma

- Phase 2 Clinical Trial Targeted to Commence in 2022 - WILMINGTON, Del. & BOSTON --(BUSINESS WIRE)--Jan. 5, 2022-- NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs a…

AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer

- Former chief operating officer of Enzyvant Therapeutics brings over 20 years of biotech leadership experience - BOSTON --(BUSINESS WIRE)--Dec. 1, 2021-- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as
Show more

AVEO Pharmaceuticals Frequently Asked Questions

  • When was AVEO Pharmaceuticals founded?

    AVEO Pharmaceuticals was founded in 2001.

  • Who are AVEO Pharmaceuticals key executives?

    AVEO Pharmaceuticals's key executives are Erick Lucera, Kenneth M. Bate and Michael P. Bailey.

  • How many employees does AVEO Pharmaceuticals have?

    AVEO Pharmaceuticals has 19 employees.

  • What is AVEO Pharmaceuticals revenue?

    Latest AVEO Pharmaceuticals annual revenue is $6 m.

  • What is AVEO Pharmaceuticals revenue per employee?

    Latest AVEO Pharmaceuticals revenue per employee is $316.8 k.

  • Who are AVEO Pharmaceuticals competitors?

    Competitors of AVEO Pharmaceuticals include Moleculin Biotech, Plus Therapeutics and Jiangsu Hansoh Pharmaceutical Group.

  • Where is AVEO Pharmaceuticals headquarters?

    AVEO Pharmaceuticals headquarters is located at 30 Winter Pl, Boston.

  • Where are AVEO Pharmaceuticals offices?

    AVEO Pharmaceuticals has an office in Boston.

  • How many offices does AVEO Pharmaceuticals have?

    AVEO Pharmaceuticals has 1 office.